Latest News

An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.
Blinatumomab-Related ICANS Symptoms More Prevalent Than Prior Reports

April 11th 2025

An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.
Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis

March 17th 2025

Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies

March 17th 2025

Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.
Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies

March 7th 2025

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.
Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

February 14th 2025

More News